Recombinant Sclerotium Rolfsii Lectin for Targeted Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases are costly, have significant side effects, and lack specificity, necessitating a more effective and economical biologic option.
Innovation Solution
Utilization of a recombinant lectin derived from Sclerotium rolfsii with an amino acid sequence of SEQ ID NO: 2, which inhibits inflammatory cytokine secretion, reduces C-reactive protein levels, and stimulates ALP activity and collagen levels, administered via various routes to treat and prevent inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications (NSAIDs, DMARDs, biologics, corticosteroids) are used to treat inflammatory diseases, then inflammation can be reduced, but cost increases and side effects occur
Solution Approach 1:
The patent employs a recombinant lectin protein derived from Sclerotium rolfsii, which is a cost-effective alternative to expensive biologics. The lectin is produced through recombinant DNA technology in host cells, enabling scalable production at lower cost while maintaining therapeutic efficacy with fewer side effects
Solution Approach 2:
The patent modifies the amino acid sequence of the Sclerotium rolfsii lectin (SEQ ID NO: 2) to enhance its anti-inflammatory properties. Specific amino acid changes were introduced to improve binding affinity and functional activity, allowing optimization of therapeutic parameters without increasing cost
2Manufacturing precision
If biologics are used to treat inflammatory diseases, then specificity and efficacy improve, but cost and availability worsen
Solution Approach 1:
The patent creates a recombinant copy of the Sclerotium rolfsii lectin protein using DNA cloning techniques. The gene encoding the lectin is inserted into host cells (such as E. coli or yeast) that replicate and produce the protein, enabling large-scale manufacturing while maintaining the specific anti-inflammatory properties of the original lectin
Solution Approach 2:
The recombinant lectin protein serves multiple functions: it binds to specific carbohydrate structures on cell surfaces, activates immune cells, and modulates inflammatory responses. This multi-functionality allows a single protein to address various aspects of inflammatory disease pathology, reducing the need for multiple specialized drugs
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 1.